Travere Therapeutics Inc. Common Stock (TVTX)

FairStock Score: 33/100 — RISKY

Key Financials

Strengths

• Revenue growth of 73.4% demonstrates strong top-line momentum

Concerns

• High leverage at 3.32x debt-to-equity increases financial risk and interest expense burden
• Altman Z-Score of 1.7 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Travere Therapeutics Inc. Common Stock is a small-cap healthcare company valued at $3.7 billion. The business generates $536 million in annual revenue with a 0.5% net margin. From a quality standpoint, Travere shows distressed Altman Z-Score of 1.7 warrants caution and negative ROE indicating losses. On valuation, the stock is 1.1% FCF yield. Growth dynamics show revenue growing at 73.4% and profit growth of 104.5%. Our composite FairStock Score of 33/100 reflects below-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Travere's 73% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Elevated leverage at 3.3x D/E means rising interest rates or revenue weakness could strain debt covenants and force asset sales at distressed prices. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer